JP2021500028A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021500028A5 JP2021500028A5 JP2020522004A JP2020522004A JP2021500028A5 JP 2021500028 A5 JP2021500028 A5 JP 2021500028A5 JP 2020522004 A JP2020522004 A JP 2020522004A JP 2020522004 A JP2020522004 A JP 2020522004A JP 2021500028 A5 JP2021500028 A5 JP 2021500028A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence represented
- represented
- antibody
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 claims 43
- 125000003275 alpha amino acid group Chemical group 0.000 claims 35
- 108091026890 Coding region Proteins 0.000 claims 30
- 238000000034 method Methods 0.000 claims 25
- 239000002773 nucleotide Substances 0.000 claims 22
- 125000003729 nucleotide group Chemical group 0.000 claims 22
- 210000003719 b-lymphocyte Anatomy 0.000 claims 21
- 241000700605 Viruses Species 0.000 claims 12
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 108020005004 Guide RNA Proteins 0.000 claims 5
- 230000002068 genetic effect Effects 0.000 claims 5
- 206010022000 influenza Diseases 0.000 claims 4
- 101710163270 Nuclease Proteins 0.000 claims 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 3
- 238000003780 insertion Methods 0.000 claims 3
- 230000037431 insertion Effects 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 102000003390 tumor necrosis factor Human genes 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 claims 2
- 201000005702 Pertussis Diseases 0.000 claims 2
- 230000036436 anti-hiv Effects 0.000 claims 2
- 230000002924 anti-infective effect Effects 0.000 claims 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims 2
- 230000003097 anti-respiratory effect Effects 0.000 claims 2
- 238000003776 cleavage reaction Methods 0.000 claims 2
- 210000001806 memory b lymphocyte Anatomy 0.000 claims 2
- 230000002093 peripheral effect Effects 0.000 claims 2
- 230000007017 scission Effects 0.000 claims 2
- 238000002255 vaccination Methods 0.000 claims 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 1
- 231100000699 Bacterial toxin Toxicity 0.000 claims 1
- 108091033409 CRISPR Proteins 0.000 claims 1
- 208000001490 Dengue Diseases 0.000 claims 1
- 206010012310 Dengue fever Diseases 0.000 claims 1
- 241000702421 Dependoparvovirus Species 0.000 claims 1
- 108010008165 Etanercept Proteins 0.000 claims 1
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims 1
- 206010054094 Tumour necrosis Diseases 0.000 claims 1
- 229950004283 actoxumab Drugs 0.000 claims 1
- 229960002964 adalimumab Drugs 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000001512 anti-cytomegaloviral effect Effects 0.000 claims 1
- 230000003622 anti-hsv Effects 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 239000000688 bacterial toxin Substances 0.000 claims 1
- 229950008086 bezlotoxumab Drugs 0.000 claims 1
- 238000010322 bone marrow transplantation Methods 0.000 claims 1
- 229960003115 certolizumab pegol Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 208000025729 dengue disease Diseases 0.000 claims 1
- 238000004520 electroporation Methods 0.000 claims 1
- 229960000403 etanercept Drugs 0.000 claims 1
- 238000010362 genome editing Methods 0.000 claims 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 229960000598 infliximab Drugs 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 229960000402 palivizumab Drugs 0.000 claims 1
- 230000003248 secreting effect Effects 0.000 claims 1
- 238000011269 treatment regimen Methods 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023190846A JP7650336B2 (ja) | 2017-10-20 | 2023-11-08 | 選択された抗体を発現するように遺伝子改変されたb細胞を産生するシステム及び方法 |
| JP2025038002A JP2025090718A (ja) | 2017-10-20 | 2025-03-11 | 選択された抗体を発現するように遺伝子改変されたb細胞を産生するシステム及び方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762575275P | 2017-10-20 | 2017-10-20 | |
| US62/575,275 | 2017-10-20 | ||
| US201762580303P | 2017-11-01 | 2017-11-01 | |
| US62/580,303 | 2017-11-01 | ||
| US201862623371P | 2018-01-29 | 2018-01-29 | |
| US62/623,371 | 2018-01-29 | ||
| PCT/US2018/056789 WO2019079772A1 (en) | 2017-10-20 | 2018-10-19 | SYSTEMS AND METHODS FOR GENETICALLY MODIFIED B-LYMPHOCYTES FOR EXPRESSING SELECTED ANTIBODIES |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023190846A Division JP7650336B2 (ja) | 2017-10-20 | 2023-11-08 | 選択された抗体を発現するように遺伝子改変されたb細胞を産生するシステム及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021500028A JP2021500028A (ja) | 2021-01-07 |
| JP2021500028A5 true JP2021500028A5 (cg-RX-API-DMAC7.html) | 2021-11-25 |
| JP7383607B2 JP7383607B2 (ja) | 2023-11-20 |
Family
ID=66174267
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020522004A Active JP7383607B2 (ja) | 2017-10-20 | 2018-10-19 | 選択された抗体を発現するように遺伝子改変されたb細胞を産生するシステム及び方法 |
| JP2023190846A Active JP7650336B2 (ja) | 2017-10-20 | 2023-11-08 | 選択された抗体を発現するように遺伝子改変されたb細胞を産生するシステム及び方法 |
| JP2025038002A Pending JP2025090718A (ja) | 2017-10-20 | 2025-03-11 | 選択された抗体を発現するように遺伝子改変されたb細胞を産生するシステム及び方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023190846A Active JP7650336B2 (ja) | 2017-10-20 | 2023-11-08 | 選択された抗体を発現するように遺伝子改変されたb細胞を産生するシステム及び方法 |
| JP2025038002A Pending JP2025090718A (ja) | 2017-10-20 | 2025-03-11 | 選択された抗体を発現するように遺伝子改変されたb細胞を産生するシステム及び方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11578118B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3697895A4 (cg-RX-API-DMAC7.html) |
| JP (3) | JP7383607B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR102723182B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN119265240A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2018351072B9 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112020007823A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3079681A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL274082B2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX428371B (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202003024WA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019079772A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108486125B (zh) * | 2018-03-27 | 2024-01-05 | 重庆金迈博生物科技有限公司 | 一种核酸分子及其在制备人源单域抗体中的应用 |
| WO2020053865A1 (en) * | 2018-09-13 | 2020-03-19 | Ramot At Tel-Aviv University Ltd. | Genetic engneering of b cell receptors and uses thereof in antigen-induced antibody secretion |
| CN111995674B (zh) * | 2020-09-03 | 2022-02-11 | 中国人民解放军军事科学院军事医学研究院 | 抗COVID-19病毒中和抗体mhC3及其人源化抗体与应用 |
| WO2023192936A2 (en) * | 2022-03-30 | 2023-10-05 | Fred Hutchinson Cancer Center | Systems and methods to produce b cells that express selected antibodies and gene products |
| AU2023269134A1 (en) * | 2022-05-09 | 2024-12-12 | Regeneron Pharmaceuticals, Inc. | Vectors and methods for in vivo antibody production |
| WO2025096483A2 (en) * | 2023-10-30 | 2025-05-08 | Be Biopharma, Inc. | Engineered cell preparations |
| CN121801968B (zh) * | 2026-03-10 | 2026-07-03 | 南京拂晓生物科技有限公司 | 一种用于生物融合酶抗体制备的免疫动物模型构建方法及其应用 |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020102257A1 (en) * | 1998-09-21 | 2002-08-01 | Leslie Sid Johnson | Human-murine chimeric antibodies against respiratory syncytial virus |
| US5604090A (en) | 1994-06-06 | 1997-02-18 | Fred Hutchinson Cancer Research Center | Method for increasing transduction of cells by adeno-associated virus vectors |
| US20010034062A1 (en) * | 2000-02-09 | 2001-10-25 | Scott Koenig | Antibody gene therapy with adeno-associated viral vectors |
| AU2001270252B2 (en) * | 2000-07-03 | 2007-02-08 | Catalent Pharma Solutions, Llc | Expression vectors |
| AU7658101A (en) * | 2000-07-28 | 2002-02-13 | Cytos Biotechnology Ag | Compositions for inducing self-specific anti-ige antibodies and uses thereof |
| DE10113776B4 (de) | 2001-03-21 | 2012-08-09 | "Iba Gmbh" | Isoliertes streptavidinbindendes, kompetitiv eluierbares Peptid, dieses umfassendes Fusionspeptid, dafür codierende Nukleinsäure, Expressionsvektor, Verfahren zur Herstellung eines rekombinanten Fusionsproteins und Verfahren zum Nachweis und/oder zur Gewinnung des Fusionsproteins |
| US7696322B2 (en) * | 2003-07-28 | 2010-04-13 | Catalent Pharma Solutions, Inc. | Fusion antibodies |
| WO2006115800A2 (en) * | 2005-04-15 | 2006-11-02 | The Regents Of The University Of California | Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha |
| JP2009532027A (ja) * | 2006-03-28 | 2009-09-10 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 抗igf−1r抗体およびその使用 |
| AU2010232414A1 (en) * | 2009-04-03 | 2011-10-13 | Duke University | Mouse models |
| DK3241435T3 (da) | 2009-07-08 | 2021-08-23 | Kymab Ltd | Dyremodeller og terapeutiske molekyler |
| JP2013508308A (ja) * | 2009-10-23 | 2013-03-07 | ガーバン インスティテュート オブ メディカル リサーチ | 修飾可変ドメイン分子、ならびにその産生および使用方法 |
| DK2521789T3 (en) * | 2010-01-08 | 2017-03-27 | Immusoft Corp | VECTORS AND PROCEDURE FOR B-CELL TRANSDUCTION |
| EP2591000B1 (en) | 2010-07-09 | 2017-05-17 | Janssen Vaccines & Prevention B.V. | Anti-human respiratory syncytial virus (rsv) antibodies and methods of use |
| US8637035B2 (en) | 2010-07-16 | 2014-01-28 | Academia Sinica | Anti-dengue virus antibodies |
| CN103282385A (zh) | 2010-11-12 | 2013-09-04 | 美国洛克菲勒大学 | 用于hiv治疗的融合蛋白 |
| EP2663334A4 (en) | 2011-01-10 | 2016-01-13 | Univ Emory | ANTIBODIES AGAINST INFLUENZA |
| LT2748201T (lt) | 2011-08-23 | 2018-02-26 | Roche Glycart Ag | Dvigubai specifinė t ląsteles aktyvinantį antigeną surišanti molekulė |
| GB201122047D0 (en) | 2011-12-21 | 2012-02-01 | Kymab Ltd | Transgenic animals |
| US20150056171A1 (en) * | 2012-03-16 | 2015-02-26 | University Of Rochester | Methods of Predicting Clinical Outcome of Chronic Lymphocytic Leukemia |
| WO2013148256A2 (en) * | 2012-03-27 | 2013-10-03 | Dana-Farber Cancer Institute, Inc. | Compositions, kits, and methods for the generation of immunoglobulin sequences |
| CN116622704A (zh) | 2012-07-25 | 2023-08-22 | 布罗德研究所有限公司 | 可诱导的dna结合蛋白和基因组干扰工具及其应用 |
| EP3064585B1 (en) | 2012-12-12 | 2020-02-05 | The Broad Institute, Inc. | Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| EP2931899A1 (en) | 2012-12-12 | 2015-10-21 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof |
| PT2931898E (pt) | 2012-12-12 | 2016-06-16 | Harvard College | Manipulação e otimização de sistemas, métodos e composições para manipulação de sequências com domínios funcionais |
| WO2014093694A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes |
| KR102955556B1 (ko) | 2012-12-12 | 2026-04-22 | 더 브로드 인스티튜트, 인코퍼레이티드 | 서열 조작을 위한 crispr-cas 성분 시스템, 방법 및 조성물 |
| MX380562B (es) | 2012-12-12 | 2025-03-12 | Broad Inst Inc | Modificaciones de sistemas, métodos y composiciones guía optimizadas para la manipulación de secuencias. |
| WO2014093709A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof |
| SG10201707569YA (en) | 2012-12-12 | 2017-10-30 | Broad Inst Inc | Delivery, Engineering and Optimization of Systems, Methods and Compositions for Sequence Manipulation and Therapeutic Applications |
| CN105209621B (zh) | 2012-12-12 | 2021-05-25 | 布罗德研究所有限公司 | 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化 |
| US11332719B2 (en) | 2013-03-15 | 2022-05-17 | The Broad Institute, Inc. | Recombinant virus and preparations thereof |
| US10993420B2 (en) * | 2013-03-15 | 2021-05-04 | Erasmus University Medical Center | Production of heavy chain only antibodies in transgenic mammals |
| WO2014204725A1 (en) | 2013-06-17 | 2014-12-24 | The Broad Institute Inc. | Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation |
| SG11201510327TA (en) | 2013-06-17 | 2016-01-28 | Broad Inst Inc | Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells |
| ES2777217T3 (es) | 2013-06-17 | 2020-08-04 | Broad Inst Inc | Suministro, modificación y optimización de sistemas de guía en tándem, métodos y composiciones para la manipulación de secuencias |
| JP6738728B2 (ja) | 2013-06-17 | 2020-08-19 | ザ・ブロード・インスティテュート・インコーポレイテッド | 肝臓ターゲティングおよび治療のためのCRISPR−Cas系、ベクターおよび組成物の送達および使用 |
| EP3011033B1 (en) | 2013-06-17 | 2020-02-19 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof |
| WO2014204723A1 (en) | 2013-06-17 | 2014-12-24 | The Broad Institute Inc. | Oncogenic models based on delivery and use of the crispr-cas systems, vectors and compositions |
| KR20250012194A (ko) | 2013-06-17 | 2025-01-23 | 더 브로드 인스티튜트, 인코퍼레이티드 | 바이러스 구성성분을 사용하여 장애 및 질환을 표적화하기 위한 crispr-cas 시스템 및 조성물의 전달, 용도 및 치료 적용 |
| MX370565B (es) | 2013-07-19 | 2019-12-17 | Vib Vzw | Miembros de la familia tnf modificados dirigidos. |
| WO2015065964A1 (en) | 2013-10-28 | 2015-05-07 | The Broad Institute Inc. | Functional genomics using crispr-cas systems, compositions, methods, screens and applications thereof |
| WO2015089419A2 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components |
| KR20160097338A (ko) | 2013-12-12 | 2016-08-17 | 더 브로드 인스티튜트, 인코퍼레이티드 | 뉴클레오티드 반복 장애에서의 crispr-cas 시스템의 조성물 및 방법 및 용도 |
| WO2015089364A1 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Crystal structure of a crispr-cas system, and uses thereof |
| CN105899658B (zh) * | 2013-12-12 | 2020-02-18 | 布罗德研究所有限公司 | 针对hbv和病毒性疾病以及障碍的crispr-cas系统和组合物的递送、用途和治疗应用 |
| JP6793547B2 (ja) | 2013-12-12 | 2020-12-02 | ザ・ブロード・インスティテュート・インコーポレイテッド | 最適化機能CRISPR−Cas系による配列操作のための系、方法および組成物 |
| CA2932439A1 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute, Inc. | Crispr-cas systems and methods for altering expression of gene products, structural information and inducible modular cas enzymes |
| CN111206032B (zh) | 2013-12-12 | 2024-07-19 | 布罗德研究所有限公司 | 用于基因组编辑的crispr-cas系统和组合物的递送、用途和治疗应用 |
| WO2015089473A1 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation |
| NZ722391A (en) | 2014-02-04 | 2022-12-23 | Biogen Ma Inc | Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications |
| ES2755957T3 (es) | 2014-03-31 | 2020-04-24 | Univ Texas | Anticuerpos de tos ferina humanizados y usos de los mismos |
| US11897921B2 (en) | 2014-12-09 | 2024-02-13 | New York University | Propeptide fusion comprising a mutated clostridium botulinum neurotoxin and a VHH domain |
| CA2981077A1 (en) * | 2015-04-03 | 2016-10-06 | Dana-Farber Cancer Institute, Inc. | Composition and methods of genome editing of b-cells |
| US9790490B2 (en) | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
| WO2017106657A1 (en) | 2015-12-18 | 2017-06-22 | The Broad Institute Inc. | Novel crispr enzymes and systems |
| US20190264186A1 (en) | 2016-01-22 | 2019-08-29 | The Broad Institute Inc. | Crystal structure of crispr cpf1 |
-
2018
- 2018-10-19 CN CN202411382074.6A patent/CN119265240A/zh active Pending
- 2018-10-19 US US16/757,707 patent/US11578118B2/en active Active
- 2018-10-19 EP EP18869188.5A patent/EP3697895A4/en active Pending
- 2018-10-19 JP JP2020522004A patent/JP7383607B2/ja active Active
- 2018-10-19 IL IL274082A patent/IL274082B2/en unknown
- 2018-10-19 MX MX2020004063A patent/MX428371B/es unknown
- 2018-10-19 BR BR112020007823-9A patent/BR112020007823A2/pt unknown
- 2018-10-19 SG SG11202003024WA patent/SG11202003024WA/en unknown
- 2018-10-19 CN CN201880080021.5A patent/CN111479916B/zh active Active
- 2018-10-19 KR KR1020207014413A patent/KR102723182B1/ko active Active
- 2018-10-19 CA CA3079681A patent/CA3079681A1/en active Pending
- 2018-10-19 WO PCT/US2018/056789 patent/WO2019079772A1/en not_active Ceased
- 2018-10-19 AU AU2018351072A patent/AU2018351072B9/en active Active
- 2018-10-19 KR KR1020247035275A patent/KR20240156649A/ko active Pending
-
2023
- 2023-02-08 US US18/166,151 patent/US12589145B2/en active Active
- 2023-11-08 JP JP2023190846A patent/JP7650336B2/ja active Active
-
2024
- 2024-11-12 AU AU2024264571A patent/AU2024264571A1/en active Pending
-
2025
- 2025-03-11 JP JP2025038002A patent/JP2025090718A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220363771A1 (en) | Multispecific antibodies | |
| JP2022164824A (ja) | 発現強化座位の使用に基づく抗体を作製するための組成物および方法 | |
| JP7650336B2 (ja) | 選択された抗体を発現するように遺伝子改変されたb細胞を産生するシステム及び方法 | |
| JP2024016201A5 (cg-RX-API-DMAC7.html) | ||
| CN106573986A (zh) | 多特异性抗体 | |
| JP2025134707A5 (cg-RX-API-DMAC7.html) | ||
| TWI922434B (zh) | 一種融合蛋白及其用途 | |
| JP2014515598A (ja) | 二重特異性三鎖抗体様分子 | |
| CA3145385A1 (en) | Antibody compositions for disrupting biofilms | |
| CN113710688A (zh) | 用于治疗血液癌症和实体瘤癌症的嵌合抗原受体修饰的t细胞(car-t) | |
| WO2016145385A2 (en) | Pan-ebola and pan-filovirus protective epitopes, antibodies, and antibody cocktails | |
| JP2022185053A (ja) | 腸内消化に対する改善された安定性を有する抗体 | |
| JP2024546759A5 (cg-RX-API-DMAC7.html) | ||
| WO2022060906A1 (en) | Coronavirus antibodies and uses thereof | |
| EP4628095A1 (en) | Fusion protein and granulated antigen comprising same | |
| CN109929033A (zh) | 一种特异性结合四种血清型登革病毒的人源抗体 | |
| CN101831434B (zh) | 抗人cd45ra鼠免疫球蛋白可变区基因及用途 | |
| JP2025500806A5 (cg-RX-API-DMAC7.html) | ||
| CN120399078B (zh) | 靶向cd117的纳米抗体及其应用 | |
| JP2025500805A5 (cg-RX-API-DMAC7.html) | ||
| CN103087155A (zh) | 一种狂犬病毒疫苗增效蛋白及编码该蛋白的基因和应用 | |
| WO2017156423A2 (en) | Broadly protective antibody cocktails for treatment of filovirus hemorrhagic fever | |
| EP3525813B1 (en) | Broadly neutralizing antibody targeting the ebolavirus glycoprotein internal fusion loop | |
| RU2815823C2 (ru) | Выделенное биспецифическое антитело, которое специфически связывается с CD47 и PD-L1 | |
| CN100412193C (zh) | 抗人cd19鼠免疫球蛋白可变区基因及用途 |